Today, around 550 million people live with a heart or cardiovascular disease, which represents 1 out of 14 people worldwide (British Heart Foundation).
Improving these lives though medical progress relies upon active investors such as Jean Boulle Group to identify opportunities, make investment, assemble scientific teams and complete the clinical trials required to develop new devices.
As lead investor, the Group attracted large scale co-investment which allowed the technology to develop further and enter commercialisation and international roll out.